Electromed, Inc. (ELMD)

Over the past six months, Electromed, Inc. has experienced several events that have impacted its stock price. The company announced record financial results for its fiscal second quarter of 2026, reporting significant increases in net revenues, operating income, and net income, leading to a stock increase. Electromed announced its Q1 FY 2026 results, with increases in net revenues and net income. Electromed repurchased a significant amount of its common stock and had a stock repurchase authorization approved. The company participated in various investor conferences. Electromed was added to the Russell indexes. Over the past 12 months, the stock has gained value and has traded between a 52-week high and low.

Specific seasonal fluctuations in demand for Electromed, Inc.'s products and services were not explicitly detailed in the available information. The overall market for HFCWO devices is projected to grow due to an aging U.S. population, increasing recognition and diagnosis of non-cystic fibrosis bronchiectasis, and improved diagnostic tools and clinical studies.

Electromed, Inc. is a medical technology company specializing in airway clearance therapy products, operating in the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry. Its flagship product is the SmartVest Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) technology and is prescribed for patients with compromised pulmonary function, including those with bronchiectasis, cystic fibrosis, and neuromuscular conditions. The company also offers the SmartVest SQL System, the SmartVest Clearway System, SmartVest Connect, Single Patient Use (SPU) SmartVest, and SmartVest Wrap products.

Electromed, Inc. is headquartered in New Prague, Minnesota, United States. The company markets its products in the U.S. to both the home health care and institutional markets, for use by patients in personal residences, hospitals, and clinics. Electromed also sells its products internationally, both directly and through distributors.

Electromed, Inc. has demonstrated strong financial performance, contributing positively to its brand reputation. The company emphasizes its role as a leader in innovative airway clearance technologies and its focus on HFCWO therapy. However, the company operates in a highly competitive market, and there have been discussions questioning the comparative efficacy of HFCWO versus alternative airway clearance therapies. Electromed's strategy involves highlighting its devices' comfort and quietness, and its high-touch patient training model.

Electromed, Inc. has a mixed ownership structure, with institutional, retail, and individual investors. A significant portion of the company's stock is owned by Institutional Investors, Insiders, Public Companies and Individual Investors. Major institutional and individual owners are listed.